Evidence map›Paper›PMID 41743466›Full record

ReviewFrontiers in aging neuroscience2026

ZCCHC17: a target for synaptic dysfunction and neuronal excitability in Alzheimer's disease.

Brittany A Klub, Andrew F Teich, Giuseppe P Cortese

Abstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brittany A KlubTouro College of Osteopathic Medicine, Touro University, Great Falls, MT, United States.
Andrew F TeichDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Giuseppe P CorteseTouro College of Osteopathic Medicine, Touro University, Great Falls, MT, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epileptic activity and neuronal excitability have been reported in the setting of Alzheimer's disease (AD), and may be linked to disease progression and severity. A shift in the excitation/inhibition balance to favor a more excitatory-dominant outcome appears to underlie the overall hyperactivity, with key mechanisms known to regulate excitatory and inhibitory neurotransmission in the brain being primarily affected. Synaptic dysfunction is a critical event in AD pathogenesis. Recent research suggests that the zinc finger protein, ZCCHC17 (Zinc Finger CCHC-Type Containing 17), serves as a potential master regulator of synaptic dysfunction in AD, with expression significantly reduced in the AD brain prior to gliosis and neuronal loss. Reduced levels of ZCCHC17 have been shown to lead to abnormal RNA processing and neuronal hyperexcitability. This review examines the specific role of ZCCHC17 in the AD brain, and discusses how ZCCHC17 may regulate mechanisms that underlie neuronal hyperexcitability. New insight into synaptic regulators of disease may contribute to improvements in early-stage diagnostics and interventions, and may better guide therapeutic approaches aimed at rescuing synaptic dysfunction in the prodromal stages of AD.

Indexed as

Alzheimer’s disease (AD)neuronal excitabilityneuronal hyperexcitabilitysynaptic dysfunctionsynaptic gene expressionZCCHC17

Identifiers

PMID41743466
PMCPMC12929414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.